ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study

2Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Treatment criteria for chronic hepatitis B (CHB) relies on ALT, which can be impacted by concurrent nonalcoholic fatty liver disease (NAFLD), but ALT data on patients with CHB and NAFLD are limited. We aimed to characterize ALT distribution in untreated CHB patients with NAFLD. Methods: We retrospectively analyzed untreated US adults with CHB (533 with NAFLD, 3,172 without NAFLD) using the Clinformatics™ Data Mart Database (2003-2019). The main outcome was ALT elevation (>1× upper limit of normal, 35/25 U/L for men/women, respectively). Secondary outcomes were advanced fibrosis (via FIB-4 index) and factors associated with fibrosis. Results: The majority of patients were Asian (61.0%) and hepatitis B e-Antigen (HBeAg)-negative (90.4%). Patients with CHB and NAFLD were older (57.2 vs. 49.5 years, p < 0.001), more likely male (59.3% vs. 46.2%, p < 0.001), with higher percentages of advanced fibrosis (3.6% vs. 2.6%, p < 0.001) than those with CHB alone. CHB-NAFLD patients were more likely to have elevated ALT than those with CHB only, but this difference was only significant among those with low hepatitis B virus (HBV) DNA (38.1% vs. 25.6%, p < 0.001), not those with higher HBV DNA (>2,000 IU/mL). After adjusting for HBeAg, HBV DNA, and diabetes, NAFLD was not independently associated with advanced fibrosis (odds ratio 1.18, 95% confidence interval: 0.30-4.59, p = 0.81). Discussion: CHB-NAFLD patients with HBV DNA below treatment threshold were more likely to have elevated ALT but not those with higher HBV DNA, suggesting that ALT threshold does not need to be raised for antiviral eligibility for CHB with NAFLD.

References Powered by Scopus

Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes

8102Citations
N/AReaders
Get full text

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

4462Citations
N/AReaders
Get full text

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

3668Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta-analysis

2Citations
N/AReaders
Get full text

Air pollution causes abnormal alanine aminotransferase levels in patients with chronic hepatitis B

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chang, C. Y., Kam, L., Dang, N., Cheung, R., & Nguyen, M. H. (2022). ALT Levels in Treatment-Naive, Chronic Hepatitis B Patients with Concurrent Fatty Liver Disease: A US Nationwide Study. Digestive Diseases, 40(4), 497–505. https://doi.org/10.1159/000518645

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

50%

Researcher 3

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Biochemistry, Genetics and Molecular Bi... 1

20%

Nursing and Health Professions 1

20%

Immunology and Microbiology 1

20%

Save time finding and organizing research with Mendeley

Sign up for free